The vaccine will be supplied by Moderna and distributed in Japan by Takeda Pharmaceutical starting in the first half of 2021 if the vaccine candidate receives regulatory approval.
Moderna announced on Aug. 28, 2020 that it is in discussions with the Ministry of Health, Labour and Welfare of Japan (MHLW) to purchase 40 million or more doses of mRNA-1273, Moderna’s COVID-19 vaccine candidate.
Through the agreement, the vaccine will be supplied by Moderna and distributed in Japan by Takeda Pharmaceutical starting in the first half of 2021 if the vaccine candidate receives regulatory approval, a Moderna press release said.
Source: Moderna
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.